In July 2005, positive results of erlotinib targeting EGFR in unselected patients with non-small cell lung cancer (NSCLC) were published.19 Erlotinib was first offered to Danish patients selected by clinical and histological characteristics by referral to centers abroad and later to the Experimental Units in Denmark. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.